Chiltern keeps quiet over possible sale
This article was originally published in Scrip
The UK-based CRO Chiltern International has refused to comment on industry speculation that is it up for sale for approximately £200 million by its private equity owners Czura Thornton.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"